Skip to main content
. 2022 Apr 13;10(1):267–283. doi: 10.1016/j.gendis.2022.04.001

Figure 11.

Fig. 11

Hypothetical model. We illustrate the experimental approach of employing AlphaLISA-based HTS to identify two FDA-approved drugs, Clo and Can. Both drugs offer potential for use in new indications via their ability to inhibit PRMT5-mediated NF-κB activation, therefore, the expression of its downstream genes in PDAC, CRC and BC. This effect may eventually lead to an inhibition of tumor phenotype, thereby highlighting the potential of Clo and Can to be repurposed for new indications in cancer patients.